BCL2 and melanoma: In a separate study, CRISPR/Cas9 mediated knockout of BFL-1 in melanoma cells were not sensitized to pharmacological inhibition of MCL-1, BCL-XL, and BCL-2 indicating that the melanoma cells do not rely on BFL-1 for survival [21].